Possible mechanism involved in the anticonvulsant action of butorphanol in mice

• Published in: Pharmacology, biochemistry and behavior biochemistry and behavior, 2003, Vol.74 (2), p.343-350
• Main Authors: Manocha, Anshu, Sharma, Krishna Kishore, Mediratta, Pramod Kumari
• Format: Article
• Language: English
• Subjects: Analgesics, Opioid - antagonists & inhibitors; Analgesics, Opioid - pharmacology; Animals; Anticonvulsants; Anticonvulsants. Antiepileptics. Antiparkinson agents; Benzomorphans - pharmacology; Biological and medical sciences; Butorphanol; Butorphanol - antagonists & inhibitors; Butorphanol - pharmacology; Convulsions; Dose-Response Relationship, Drug; Electroshock; Female; Ligands; Male; Maximal electroshock; Medical sciences; Mice; N-Methyl- d-aspartate; Naloxone - pharmacology; Narcotic Antagonists - pharmacology; Neuropharmacology; Opioids; Pharmacology. Drug treatments; Receptors, GABA-A - drug effects; Receptors, GABA-B - drug effects; γ-Aminobutyric acid
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/S0091-3057(02)01004-3

The study was designed to examine the effect of butorphanol, a classical opioid on convulsive behaviour using maximal electroshock (MES) test. An attempt was also made to investigate the role of possible receptor mechanisms involved. MES seizures were induced in mice via transauricular electrodes (60 mA, 0.2 s). Seizure severity was assessed by the duration of tonic hindlimb extensor phase and mortality due to convulsions. Intraperitoneal administration of butorphanol produced a dose-dependent (0.25–2 mg/kg) protection against hindlimb extensor phase. The anticonvulsant effect of butorphanol was antagonized by all the three opioid receptor antagonists (i.e., naloxone [mu], MR2266 [kappa], and naltrindole [delta], respectively). Coadministration of γ-aminobutyric acid (GABA)-ergic drugs (diazepam, GABA, muscimol, and baclofen) and N-methyl- d-aspartate (NMDA) receptor antagonist, dizocilpine (MK801), with butorphanol augmented the anticonvulsant action of the latter drug. In contrast, flumazenil, a central benzodiazepine (BZD) receptor antagonist, reversed the facilitatory effect of diazepam on the anti-MES effect of butorphanol. Similarly, δ-aminovaleric acid (DAVA), a GABA B receptor antagonist, antagonized the facilitatory effect of baclofen, a GABA B agonist on anti-MES action of butorphanol. These BZD–GABAergic antagonists, flumazenil or DAVA, per se also counteracted the anti-MES effect of butorphanol given alone. These data exemplify the benefits of using the MES test, which is sensitive to opioidergic compounds and distinguished convulsive behavioural changes associated with GABAergic and NMDAergic effects. Taken together, the results implicate a role for multitude of neurotransmitter systems, i.e., opioid (mu, kappa, delta), NMDA channel, BZD–GABA A chloride channel complex, and GABA B receptors in the anti-MES action of butorphanol.